SHENYANG, China, April 12, 2010 -- NF Energy Saving Corporation (OTCBB: NFEC; "NF Energy"), a Chinese leader in providing integrated energy conservation solutions, today commented on the recent release of the People's Republic of China's State Council Plan, "Opinion on Accelerating the Implementation of Energy Management Contract to Promote the Development of Energy Service Industry," ("the Opinion"), which outlines the development goal, financial subsidies, preferential tax policies, accounting policies and pilot projects, etc. for the Energy Service Industry in China.
NF Energy Saving Corporation closed at $3.91 Friday, trading 32,650 shares.
NF Energy Saving Corporation Comments on The People's Republic of China's Important New Incentive Policies in Support of the Energy Service Industry
About NF Energy Saving Corporation
NF Energy Saving Corporation (OTCBB: NFEC) is a China-based provider of integrated energy conservation solutions utilizing energy-saving equipment, technical services and energy management re-engineering project operations to provide energy saving services to clients. The current revenues are primarily from its energy saving flow control products. Headquartered in Shenyang city of China, the Company currently has 225 employees and several proprietary energy saving technologies and patents.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
GREENWOOD VILLAGE, Colo., April 12, 2010-- Ampio Pharmaceuticals, Inc. (OTCBB: AMPE) announced today the signing of a contract with St. Michael's Hospital, Toronto, Canada to conduct, "A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Three Doses of Oral Optina™ in Adult Subjects with Diabetic Macular Edema".
Ampio Pharmaceuticals, Inc. closed at $4.00 Friday, trading 600 shares.
Ampio Pharmaceuticals Contracts with St. Michael's Hospital to Conduct Phase II Clinical Trial of Optina(TM) to Treat Diabetic Retinopathy
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc. develops drugs to treat metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The company's product pipeline includes certain FDA approved drugs, now targeted at new clinical indications protected by Ampio intellectual property, and new molecular entities ("NMEs"). The company's development of new uses for previously approved drugs is expected to result in reduced approval timelines, lower costs and decreased risks of clinical failure. The company is actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's near term and long term product development programs.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
StockProfiler.US Announcement!
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://stockprofiler.us/index.php?action=main.register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------
Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com, http://www.fastmoneytalk.com, http://www.markettelegraph.com, http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://stockprofiler.us/?action=main.disclaimer
-------------------------------------------
Keywords: small cap stock, small cap news, small cap stock alerts, small cap stock updates, small cap stock news updates, small cap stock profile
Posts
No comments:
Post a Comment